Kailera Therapeutics, Inc. Debt Securities, Available-for-sale, Unrealized Loss Position
Kailera Therapeutics, Inc. (KLRA) had Debt Securities, Available-for-sale, Unrealized Loss Position of $977.80 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale, Unrealized Loss Position
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition · last filed 2026-08-12
- 2026-06-30: Debt Securities, Available-for-sale, Unrealized Loss Position $977.80M.
- 2026-03-31: Debt Securities, Available-for-sale, Unrealized Loss Position $418.20M.
- 2025-12-31: Debt Securities, Available-for-sale, Unrealized Loss Position $79.00M.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss Position |
|---|---|
| 2026-06-30 | $977.80M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $418.20M 10-Q · filed 2026-05-26 |
| 2025-12-31 | $79.00M 10-Q · filed 2026-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |